Capricor Therapeutics, Inc. (CAPR)

Market Cap	525.28M
Revenue (ttm)	22.27M
Net Income (ttm)	-40.47M
Shares Out	45.68M
EPS (ttm)	-1.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,191,267
Open	11.79
Previous Close	11.82
Day's Range	11.06 - 11.85
52-Week Range	3.52 - 23.40
Beta	4.11
Analysts	Strong Buy
Price Target	39.29 (+241.65%)
Earnings Date	Mar 19, 2025

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: CAPR
• Website: https://www.capricor.com

Financial Performance

In 2024, Capricor Therapeutics's revenue was $22.27 million, a decrease of -11.55% compared to the previous year's $25.18 million. Losses were -$40.47 million, 81.6% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price forecast is $39.29, which is an increase of 241.65% from the latest price.

Price Target

$39.29

(241.65% upside)

Analyst Consensus: Strong Buy